After the US and the UK, Ranbaxy suffers another patent defeat over multibillion dollar drug Lipitor in Finland. Like the US and the UK, it will appeal here as well. Thus far, its only victory has been in Austria.
The Financial Express states:
In another setback to India’s biggest drugmaker Ranbaxy Laboratories Ltd, a court in Finland has prohibited it from marketing its generic version of Pfizer’s cholesterol lowering drug Lipitor in the country.
The Helsinki court of appeal in Finland had granted a preliminary injunction against Ranbaxy Laboratories prohibiting it from marketing a generic version of Lipitor.
The ruling involves Pfizer’s patent that covers processes and intermediate compounds used to make atorvastain, the active ingredient in Lipitor